Skip to main content

Table 1 Tumor, treatment, and outcome characteristics of patients providing human SCC cell lines

From: Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-κB and other signal transcription factors in head and neck squamous cell carcinoma

Cell line

Age (years at diagnosis)

Sex

Stage

TNM

Primary site

Specimen site

Prior therapy

Status

Survival (months)

UM-SCC 1

72

M

I

T1N0M0

FOM

Local recur

R

DWOD

15

UM-SCC 5

59

M

III

T2N1M0

Supraglottic larynx

Pri bx

S

DOD

8

UM-SCC 6

37

M

II

T2N0M0

Tongue

Pri bx

N

LTF

 

UM-SCC 9

72

F

II

T2N0M0

Tonsil/BOT

Local recur

R

DOD

15

UM-SCC 11A

65

M

V

T2N2aM0

Hypopharynx

Pri bx

N

DOD

14

UM-SCC 11B

     

Pri resect

C

  

UM-SCC 22A

59

F

III

T2N1M0

Hypopharynx

Pri bx

N

DOD

10

UM-SCC 22B

     

LN met

N

  

UM-SCC 38

60

M

IV

T2N2aM0

Tonsil/BOT

Pri

N

DOD

11

UM-SCC 46

57

F

III

No TMN Given

Suprglottic larynx

Local recur

R, S

DOD

6

  1. The clinical information was kindly provided by Drs Thomas E Carey and Carol R Bradford, and some information was previously presented in the literature. 'Primary sites' refers to the origin of the primary tumor. 'Specimen site' refers to origin of tissue used to establish cultures. 'Prior therapy' refers to therapy given before the specimen used for culture was obtained. 'Survival' represents time in months from diagnosis to last follow up. BOT, base of tongue; bx, biopsy; C, chemotherapy; DOD, died with disease; DWOD, died without disease; F, female; FOM, floor of mouth; LN, lymph nodes; LTF, lost to follow-up; M, male; met, metastasis; N, none; NED, no evidence of disease; Pri, primary tumor site; R, radiation; recur, recurrence; resect, surgical resection specimen; SCC, squamous cell carcinoma; S, surgery; TNM, tumor-node-metastasis (staging system); UM-SCC, University of Michigan series head and neck squamous cell carcinoma.